News
FDA plans to phase out animal testing in drugs in what it calls a ‘paradigm shift’
On Thursday, shares in Charles River Laboratories, a leading contract research organizations that has stirred controversy over its use of non-human primates, plunged 28 percent after the FDA issued its announcement.
A former top FDA official said it’s only a matter of time before the chaos at the agency starts to impact drug reviews.
The firings this week also include all staff responsible for managing records – such as new product applications – at FDA ...
A study led by two undergraduate students at the University of Galway found that GLP-1 receptor agonists, a type of diabetes ...
The Drug Allergy History Tool, which relies on patient symptom reporting, has strong reliability when compared with EHR drug allergy information.
The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.
GLP-1s are driving traditional drug spending in the U.S. to unprecedented ... and individual consumers. Claims analysis included 27.3 million members with commercial insurance coverage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback